Wave Life Sciences and Deep Genomics Inc. announced the formation of a collaboration to identify novel therapies to be developed by Wave for the treatment of genetic neuromuscular disorders.   “Wave is an industry leader in developing optimized oligonucleotides and in adopting science-based disruptive technologies,” said Brendan Frey, PhD, scientific funder and chief executive officer of Deep Genomics. “For this reason, Wave and Deep Genomics are a good match. Wave’s efforts complement o...